Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tomas Hernandez

Nurse Practitioner, Pediatrics, Critical Care Wichita, KS Nurse Practitioner

NPI 1285978544 CMS profile 10430218

550 N Hillside St, Wichita, KS 67214

Open in the dashboard

General payments

$5,363

258 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tomas Hernandez of Wichita, KS is reported in the CMS Open Payments database as having received $5,363 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Pediatrics, Critical Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,337 59
2024 General $1,338 61
2023 General $1,238 65
2022 General $1,058 50
2021 General $393 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tomas Hernandez
  • Nurse Practitioner, Pediatrics, Critical Care median
  • Middle half of Nurse Practitioner, Pediatrics, Critical Care
  • National median

In program year 2025, general payments to Tomas Hernandez were reported at $1,337. Among 229 Nurse Practitioner, Pediatrics, Critical Care profiles paid that year, the median was $80 and the middle half received between $30 and $160.

Show as a table
Year Tomas Hernandez Nurse Practitioner, Pediatrics, Critical Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $393 $42 $19–$120 $132
2022 $1,058 $56 $24–$119 $149
2023 $1,238 $77 $24–$149 $160
2024 $1,338 $61 $27–$146 $164
2025 $1,337 $80 $30–$160 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Jazz Pharmaceuticals Inc. $1,282 50 payments
  2. UCB, Inc. $1,179 71 payments
  3. AbbVie, Inc. $605 29 payments
  4. Neurelis, Inc. $455 22 payments
  5. SK Life Science, Inc. $247 11 payments
  6. Eisai Inc. $198 12 payments
  7. Supernus Pharmaceuticals, Inc. $160 4 payments
  8. Sumitomo Pharma America, Inc. $148 11 payments
  9. ACADIA Pharmaceuticals Inc $146 7 payments
  10. Marinus Pharmaceuticals, Inc. $143 6 payments
  11. Other $799 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,109 255 payments
  2. Education $254 3 payments
Products named General payments · program years 2021–2025
  1. Epidiolex $780 37 payments
  2. Briviact $650 41 payments
  3. BOTOX $524 25 payments
  4. XYWAV $502 13 payments
  5. VALTOCO $455 22 payments
  6. Fintepla $387 21 payments
  7. Fycompa $198 12 payments
  8. APTIOM $152 12 payments
  9. DAYBUE $146 7 payments
  10. ZTALMY $143 6 payments
  11. Other $1,125 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Pediatrics, Critical Care in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record